ArticleeLife2024
Design of the HPV-automated visual evaluation (PAVE) study: Validating a novel cervical screening strategy.
Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06815939 (Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer), which is not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical Cancer: Automated Visual Evaluation
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Use of Thermal Ablation in Low-Resource Settings: Experience From Three Multicenter Noninferiority Randomized Clinical Trials.JCO global oncology · 2025Pooled it
- Resource-Adapted Triage Strategies for Women Testing HPV Positive With Self-Collected Vaginal Samples in Cameroon.International journal of cancer · 2026Article
- Automated acquisition of explainable knowledge from unannotated colposcopic images for predicting the natural course of CIN2.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
- A new model for cervical cancer screening in Cambodian garment workers.BMJ global health · 2026Article
- Artificial intelligence for colposcopic and cytological image analysis in early cervical cancer detection.iScience · 2026Review
- Data-augmented multistate modeling for chronic disease processes using cross-sectional studies: application to HPV and cervical precancer.Biostatistics (Oxford, England) · 2026Article
- Evaluation and Recommendations to Modernize Cervical Cancer Detection and Prevention Programs in Brazil: Challenges and Opportunities - A Narrative Review.Acta cytologica · 2026Review
- Visual diagnostics for female genital schistosomiasis and the opportunity for improvement using computer vision.Parasitology · 2025Review
- A Novel Method for Predicting Oncogenic Types of Human Papillomavirus.Diagnostics (Basel, Switzerland) · 2025Article
- Initial evaluation of a new cervical screening strategy combining human papillomavirus genotyping and automated visual evaluation: the Human Papillomavirus-Automated Visual Evaluation Consortium.Journal of the National Cancer Institute · 2025Article
- HPV as a Molecular Hacker: Computational Exploration of HPV-Driven Changes in Host Regulatory Networks.Viruses · 2025Article
- Analytical performance of the ScreenFire HPV RS Zebra BioDome assay on four different qPCR platforms.Infectious agents and cancer · 2025Article
- A mixed-methods preliminary evaluation of an innovative treatment for cervical precancer in El Salvador's screen-and-treat program.BMC women's health · 2025Article
- Generalizable deep neural networks for image quality classification of cervical images.Scientific reports · 2025Article
- Validation of a simplified HPV genotyping assay designed for cervical screening in low-resource settings.Journal of clinical microbiology · 2025Article
- Design and validation of ultra-compact metamaterial-based biosensor for non-invasive cervical cancer diagnosis in terahertz regime.PloS one · 2025Article
- Accuracy of POC testing systems for HPV screening: the importance of disease prevalence and characteristics of the screened population.Infectious agents and cancer · 2024Article
- A cervical cancer control strategy for lower-resource settings: interventions to complement one-dose HPV vaccination.Journal of the National Cancer Institute. Monographs · 2024Article
- Looking Back, Moving Forward: Challenges and Opportunities for Global Cervical Cancer Prevention and Control.Viruses · 2024Review
- An Implementation Evaluation of the Smartphone-Enhanced Visual Inspection with Acetic Acid (SEVIA) Program for Cervical Cancer Prevention in Urban and Rural Tanzania.International journal of environmental research and public health · 2024Article
Corrections and comments
- Update of
Authors and funding
19 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The HPV-automated visual evaluation (PAVE) Study is an extensive, multinational initiative designed to advance cervical cancer prevention in resource-constrained regions. Cervical cancer disproportionally affects regions with limited access to preventive measures. PAVE aims to assess a novel screening-triage-treatment strategy integrating self-sampled HPV testing, deep-learning-based automated visual evaluation (AVE), and targeted therapies. Methods: Phase 1 efficacy involves screening up to 100,000 women aged 25-49 across nine countries, using self-collected vaginal samples for hierarchical HPV evaluation: HPV16, else HPV18/45, else HPV31/33/35/52/58, else HPV39/51/56/59/68 else negative. HPV-positive individuals undergo further evaluation, including pelvic exams, cervical imaging, and biopsies. AVE algorithms analyze images, assigning risk scores for precancer, validated against histologic high-grade precancer. Phase 1, however, does not integrate AVE results into patient management, contrasting them with local standard care.Phase 2 effectiveness focuses on deploying AVE software and HPV genotype data in real-time clinical decision-making, evaluating feasibility, acceptability, cost-effectiveness, and health communication of the PAVE strategy in practice. Results: Currently, sites have commenced fieldwork, and conclusive results are pending. Conclusions: The study aspires to validate a screen-triage-treat protocol utilizing innovative biomarkers to deliver an accurate, feasible, and cost-effective strategy for cervical cancer prevention in resource-limited areas. Should the study validate PAVE, its broader implementation could be recommended, potentially expanding cervical cancer prevention worldwide. Funding: The consortial sites are responsible for their own study costs. Research equipment and supplies, and the NCI-affiliated staff are funded by the National Cancer Institute Intramural Research Program including supplemental funding from the Cancer Cures Moonshot Initiative. No commercial support was obtained. Brian Befano was supported by NCI/ NIH under Grant T32CA09168.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.